Healthcare Industry News: stereotactic ablative radiotherapy
News Release - November 26, 2013
Over 110 Attend First Varian Edge(TM) Radiosurgery Symposium to Discuss Advances in Stereotactic Radiosurgery and Stereotactic Ablative RadiotherapyLISBON, Portugal, Nov. 26, 2013 -- (Healthcare Sales & Marketing Network) -- Leading oncology centers have reported on advances in stereotactic radiosurgery (SRS) and stereotactic ablative radiotherapy (SABR) treatments at the first Varian Edge™ Radiosurgery Symposium, held at the Champalimaud Centre for the Unknown in Lisbon, Portugal. Experts from leading centers of excellence around the world presented details of the latest in advanced treatment techniques to an audience of over 110 industry professionals.
Clinicians from Memorial Sloan Kettering Cancer Center (New York), Barnes Jewish Hospital (St. Louis), Henry Ford Health System (Detroit), Humanitas Cancer Center (Milan, Italy), VU University Medical Center (Amsterdam, Netherlands), and the Champalimaud Foundation shared details of advances in biology, targeting, speed and motion management involved in radiosurgery treatments.
"A growing body of clinical evidence demonstrates the benefits of delivering high doses in a small number of fractions, and radiosurgery can currently treat targets previously not considered candidates for high-dose hypo fractionation," says Professor Carlo Greco, of the Champalimaud Foundation. "In order to support this clinical trend and paradigm shift we are introducing a comprehensive radiosurgery system designed to shape the future of cancer care and we were delighted to be able to share our experiences with other centers from around the world."
"This symposium enabled the sharing of best practices in SRS and SABR as well as further defining and expanding the role of Edge Radiosurgery in the clinical treatment of intracranial and extracranial lesions," said Rolf Staehelin, Varian's senior director of international marketing. "Sharing knowledge and latest experiences in these areas is vital to further developing non-invasive surgical techniques in brain, spine, lung, liver, prostate and other indications."
In early 2014, Champalimaud Foundation will become the first department in the world to commence clinical treatments using the new Edge Radiosurgery system from Varian Medical Systems. This is an all-in-one system developed to aid clinicians to perform non-invasive ablative treatments throughout the body. With enhanced precision and speed, the Edge system can potentially treat a wide range of conditions across an ever increasing number of clinical indications.
Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068
ABOUT VARIAN MEDICAL SYSTEMS
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes, digital detectors, and image processing workstations for X-ray imaging in medical, scientific, and industrial applications and also supplies high-energy X-ray devices for cargo screening and non-destructive testing applications. Varian Medical Systems employs approximately 6,400 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com
Source: Varian Medical Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.